Skip to main content
Clinical Trials/RPCEC00000003
RPCEC00000003
Completed
Phase 2

Evaluation of the anti oxidating effect of the extract of Mangifera indica L. in people of the third age.

Center of Pharmaceutical Chemistry0 sites64 target enrollmentStarted: February 27, 2009Last updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
Center of Pharmaceutical Chemistry
Enrollment
64

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Other. Purpose: Prevention

Eligibility Criteria

Ages
60 years to one (—)
Sex
All

Inclusion Criteria

  • 1\. Persons with 60 year\-old or more 2\. Written acceptance and voluntary of participating in the clinical trial 3\. Good psychological conditions. 4\. People that are internal in the Home. 5\. Both sexes.

Exclusion Criteria

  • 1\. Infection systemic chronicle. 2\. Treatment with anti oxidanting in the last month. 3\. Current Hyperbaric Oxygenation or in one period of up to 15 days before the moment of their inclusion. 4\. Immunosupresive Therapy or steroids therapy in the moment of their inclusion or in the last 3 months. 5\. Renal chronicle or failure or hepatical demonstrated clinically. 6\. People with cognitive damage. 7\. People with dysphagia. 8\. People in period of convalescence (up to two weeks) of a sharp infectious illness that could alter the immune answer. 9\. Hypersensibility reaction to the components of the formulation.

Investigators

Sponsor
Center of Pharmaceutical Chemistry

Similar Trials